Philbrick Ann M, Newkirk Erin N, Farris Karen B, McDanel Deanna L, Horner Kathleen E
Department of Pharmaceutical Care and Health Systems, College of Pharmacy. University of Minnesota . Minneapolis, MN ( United States ).
Department of Pharmacy, Froedtert Hospital. Milwaukee, WI ( United States ).
Pharm Pract (Granada). 2009 Jul;7(3):150-6. doi: 10.4321/s1886-36552009000300004. Epub 2009 Mar 15.
The purpose of this study was to quantify quit rates, determine factors predicting success, and analyze patients' perceptions at 3 months after participation in the pharmacist-managed Smoking Cessation Group Clinic.
This was a prospective, single group study that was conducted in patients that had participated in the Smoking Cessation Group Clinic at the University of Iowa Hospitals and Clinics. Clinic participants received structured group counseling covering various topics associated with cessation. Varenicline, bupropion and nicotine replacement therapy were used as smoking cessation aids and selection was based on patient preference and absence of contraindications. The primary outcome of this trial was smoking status at 3 months. The patients were contacted by telephone at 3, and 6 months after the start of the clinic and asked about current smoking status. At 3 months, patients were asked to rate on a Likert scale of 1 to 5 (1=not helpful; 5=very helpful) their perceptions of individual aspects of the clinic and on a scale of 1 to 10 (1=not helpful; 10=very helpful) how they perceived their cessation aid.
From February 2007 to January 2008, 21 patients enrolled in the intent-to-treat follow up study. Analysis of data was completed in August 2008. At 3 and 6 months, 47.6% and 52.4%, of patients reported being smoke-free, respectively. At 3 months, factors consistent with success included having more previous quit attempts and type of cessation aid used. These endpoints continued to be significant at 6 months, in addition to attending more clinic sessions, and type of insurance (favoring private insurance). Patients who quit smoking rated their cessation aid as more helpful than those who did not quit smoking (8.56; SD=0.88 verses 6.71; SD=2.81, respectively; p=0.14). The aspect of the clinic most helpful to patients was group interaction (4.53; SD=0.77).
This study demonstrates that pharmacists can play a vital role with smoking cessation in a group setting. Group setting patient counseling can be an effective tool for pharmacists to reach more people within the same time frame as individual counseling.
本研究旨在量化戒烟率,确定预测成功的因素,并分析患者在参加药剂师管理的戒烟小组诊所3个月后的看法。
这是一项前瞻性单组研究,对象为参加爱荷华大学医院及诊所戒烟小组诊所的患者。诊所参与者接受涵盖与戒烟相关各种主题的结构化小组咨询。伐尼克兰、安非他酮和尼古丁替代疗法被用作戒烟辅助药物,其选择基于患者偏好和无禁忌症。本试验的主要结局是3个月时的吸烟状况。在诊所开始后的3个月和6个月通过电话联系患者,询问其当前吸烟状况。在3个月时,要求患者用1至5分制(1 = 无帮助;5 = 非常有帮助)对诊所各个方面的看法进行评分,并用1至10分制(1 = 无帮助;10 = 非常有帮助)对他们对戒烟辅助药物的看法进行评分。
从2007年2月至2008年1月,21名患者纳入意向性治疗随访研究。数据分析于2008年8月完成。在3个月和6个月时,分别有47.6%和52.4%的患者报告已戒烟。在3个月时,与成功相关的因素包括有更多以前的戒烟尝试和使用的戒烟辅助药物类型。除了参加更多诊所课程和保险类型(有利于私人保险)外,这些终点在6个月时仍然显著。戒烟的患者对其戒烟辅助药物的评价比未戒烟的患者更有帮助(分别为8.56;标准差 = 0.88对 6.71;标准差 = 2.81;p = 0.14)。对患者最有帮助的诊所方面是小组互动(4.53;标准差 = 0.77)。
本研究表明药剂师在小组环境中戒烟方面可发挥重要作用。小组环境下的患者咨询对于药剂师而言可能是一种有效的工具,能够在与个体咨询相同的时间范围内接触到更多人群。